Funded Biotechnology Startups in London
Disclosed funding amounts in this London biotechnology set are dominated by one outlier: Verdiva Bio’s $411M round dated 2025-01-09, far above the next-lar…
Disclosed funding amounts in this London biotechnology set are dominated by one outlier: Verdiva Bio’s $411M round dated 2025-01-09, far above the next-largest disclosed amounts (IMU Biosciences at $38M on 2026-06-01, R1 Therapeutics at $78M on 2026-03-17, and Purespring Therapeutics at $105M on 2024-10-09). The smallest disclosed round is Carbon Cell at $40K on 2025-10-16, sitting below the $1M floor that appears repeatedly across multiple entries (e.g., ProtonDx on 2025-12-04 at $1M; Bio-Logical on 2024-07-16 at $1M; Plasticell on 2023-08-08 at $1M).
Stages are mixed but “Series Unknown” and undisclosed amounts are common: 21 of the 50 rows list “Series Unknown,” and 3 rows show “undisclosed” funding (MYndspan on 2025-04-10; Lindus Health on 2025-04-03; xterna on 2024-12-05). Temporally, the dataset spans from 2023-07-25 (NK:IO, $2M) to 2026-06-29 (Concert Bio, $130K), with a heavy concentration in 2024–2025 rounds across London-based companies throughout.
Most recent rounds
50 of 8838 more funded startups
This page shows the 50 most recent rounds (back to Jul 2023). The full 88-company history for this listing is available on a paid plan.
Unlock all 88 companies in this listing — full funding history, investors, and founders.
Related listings
Frequently asked
Which is the largest disclosed biotech round in this London list, and how does it shape the distribution of deal sizes?
Verdiva Bio’s $411M on 2025-01-09 is the largest disclosed amount in the 50-row view and dwarfs the rest of the disclosed rounds. Even other large disclosed rounds—e.g., Pheon Therapeutics at $120M (2024-05-21) and Purespring Therapeutics at $105M (2024-10-09)—remain well below that peak.
Are there clear outliers on the low end worth flagging alongside the high outlier?
Carbon Cell’s $40K on 2025-10-16 is the smallest disclosed amount in the list. Several rounds cluster at the $1M level (e.g., ProtonDx $1M on 2025-12-04; Bio-Logical $1M on 2024-07-16; Plasticell $1M on 2023-08-08), making Carbon Cell an unusually low outlier.
How concentrated are rounds in the most recent period shown (by date), and what does that imply for tracking activity?
The newest rounds fall between 2026-06-24 and 2026-06-29 (Concert Bio $130K on 2026-06-29 and RQ Bio $113M on 2026-06-24). Looking across the top of the table, multiple entries also land in spring 2026 (e.g., IMU Biosciences 2026-06-01 $38M; Voxmind 2026-05-26 $740K), suggesting the recent window is actively populated.
What stage mix dominates, and how much of the funding/stage picture is obscured by missing labels?
“Series Unknown” accounts for 21 of 50 rows, with an additional 3 rounds marked “undisclosed” amounts (MYndspan 2025-04-10; Lindus Health 2025-04-03; xterna 2024-12-05). That means a little under half the entries either don’t specify stage or don’t disclose funding, which can materially affect analysis of stage progression.
Do the funding sizes cluster around certain thresholds (for example, $1M–$10M), or are they evenly spread?
There is a visible concentration in the low-to-mid ranges: multiple disclosed rounds sit at $2M–$9M (e.g., Anzen Industries $2M on 2026-01-19; Puraffinity $9M on 2024-09-10; Samphire Neuroscience $5M on 2025-06-03). In contrast, the largest disclosed values are comparatively rare, with the top end represented by a small set of high-ticket rounds such as Verdiva Bio ($411M), Pheon Therapeutics ($120M), and Vicebio ($100M).
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.